Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aehr Test Systems (AEHR) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Aehr Test Systems
Bio-Rad Laboratories, Inc. Class A Common Stock

Price performance

Price movement over the last 24 hours

Key statistics

Aehr Test Systems vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Aehr Test Systems trades at $68.03 (market cap $2.11B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $283.5 (market cap $7.85B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3.7× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.

AEHRBIO
Market Cap
$2.11B$7.85B
Sector
TechnologyHealth
52-Week High
$116.58$339.75
52-Week Low
$13.29$241.71
Enterprise Value
$2.08B$7.66B

Returns comparison

Trailing returns across standard periods

About Aehr Test Systems

Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.

Read more on AEHR

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO